Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma
Helen Parker,Amatta Mirandari,Carolina Jaramillo Oquendo,Martí Duran-Ferrer,Benjamin Stevens,Lara Buermann,Harindra E. Amarasinghe,Jaya Thomas,Latha Kadalayil,Louise Carr,Shama Syeda,Methusha Sakthipakan,Marina Parry,Zadie Davis,Neil McIver-Brown,Aliki Xochelli,Sarah Ennis,Lydia Scarfo,Paolo Ghia,Christina Kalpadakis,Gerassimos Pangalis,Davide Rossi,Simon Wagner,Matthew Ahearne,Marc Seifert,Christoph Plass,Dieter Weichenhan,Eva Kimby,Lesley-Ann Sutton,Richard Rosenquist,Francesco Forconi,Kostas Stamatopoulos,Marta Salido,Ana Ferrer,Catherine Thieblemont,Viktor Ljungström,Rose-Marie Amini,David Oscier,Renata Walewska,Matthew J.J. Rose-Zerilli,Jane Gibson,José Ignacio Martín-Subero,Christopher Oakes,Dean Bryant,Jonathan C Strefford
DOI: https://doi.org/10.1101/2024.01.16.24301320
2024-01-17
Abstract:The epiCMIT (epigenetically-determined Cumulative MIToses) mitotic clock traces B-cell mitotic history via DNA methylation changes in heterochromatin and H3K27me3-containing chromatin. While high scores correlated with poor outcomes in CLL and MCL, its prognostic significance in SMZL remains unknown. Derived from 142 SMZL cases using DNA methylation microarrays, epiCMIT values were correlated with genomic, transcriptomic, and clinical data. EpiCMIT as a continuous variable was significantly higher in females ( =0.02), patients with IGHV1-2*04 allele usage ( <0001), intermediate IGHV somatic hypermutation load (97-99.9% identity, =0.04), elevated mutational burden (25 vs. 17 mut/Mb, =0.001), driver gene mutations [ ( <0.001), ( <0.01), ( =0.01), ( <0.001)], and del(7q) ( =0.01). Negative correlation between epiCMIT and telomere length (r=-0.29 <0.001) supported the association between cumulated proliferation and telomere attrition. While univariate analysis highlighted epiCMIT as robust predictor of shorter treatment-free survival (TFS), multivariate analysis confirmed epiCMIT as an independent marker for shorter TFS. In summary, our matched multi-omic datasets facilitate the clinico-biological characterization of SMZL and introduces epiCMIT as a strong prognostic marker, identifying high-risk patients and predicting reduced treatment-free survival, hence providing a new tool for risk-adapted patient management.
Hematology